A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor... Support Care Cancer (2018) 26:1169–1179 https://doi.org/10.1007/s00520-017-3938-7 ORIGINAL ARTICLE A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies 1 1 2 2 Bernd Tischer & Martina Bilang & Matthias Kraemer & Philippe Ronga & Mario E. Lacouture Received: 20 July 2017 /Accepted: 23 October 2017 /Published online: 7 November 2017 The Author(s) 2017. This article is an open access publication Abstract causing pain, impairing quality of life, and proving difficult Background Inhibition of the epidermal growth factor recep- to manage. Despite these negative influences, the majority of tor (EGFR) extends patient survival in multiple tumor types. patients (71%) indicated they were willing to accept skin tox- Skin toxicities are the most common adverse event (AE) elic- icities as an AE of an effective therapy. Indeed, the majority of ited by EGFR inhibitors. Here, we provide deeper insights patients and physicians preferred a more effective therapy that into patients’ and physicians’ acceptance of the risk/benefit induces more severe skin toxicities than a less efficacious trade-offs of skin toxicities during cancer therapy, including therapy that induces less severe skin toxicities; interestingly, comparison of their perceptions and experiences with derma- patients were willing to accept a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Supportive Care in Cancer Springer Journals

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies

Loading next page...
 
/lp/springer_journal/a-survey-of-patient-and-physician-acceptance-of-skin-toxicities-from-QqM0xl4eK9
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine
ISSN
0941-4355
eISSN
1433-7339
D.O.I.
10.1007/s00520-017-3938-7
Publisher site
See Article on Publisher Site

Abstract

Support Care Cancer (2018) 26:1169–1179 https://doi.org/10.1007/s00520-017-3938-7 ORIGINAL ARTICLE A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies 1 1 2 2 Bernd Tischer & Martina Bilang & Matthias Kraemer & Philippe Ronga & Mario E. Lacouture Received: 20 July 2017 /Accepted: 23 October 2017 /Published online: 7 November 2017 The Author(s) 2017. This article is an open access publication Abstract causing pain, impairing quality of life, and proving difficult Background Inhibition of the epidermal growth factor recep- to manage. Despite these negative influences, the majority of tor (EGFR) extends patient survival in multiple tumor types. patients (71%) indicated they were willing to accept skin tox- Skin toxicities are the most common adverse event (AE) elic- icities as an AE of an effective therapy. Indeed, the majority of ited by EGFR inhibitors. Here, we provide deeper insights patients and physicians preferred a more effective therapy that into patients’ and physicians’ acceptance of the risk/benefit induces more severe skin toxicities than a less efficacious trade-offs of skin toxicities during cancer therapy, including therapy that induces less severe skin toxicities; interestingly, comparison of their perceptions and experiences with derma- patients were willing to accept a

Journal

Supportive Care in CancerSpringer Journals

Published: Nov 7, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off